|
1.
|
|
17 p, 921.2 KB |
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes
/
Sauta, Elisabetta (Humanitas Clinical and Research Center (Itàlia)) ;
Robin, Marie (Department of Hematology and Bone Marrow Transplantation. Hôpital Saint-Louis (França)) ;
Bersanelli, Mateo (Department of Biomedical Sciences. Humanitas University) ;
Travaglino, Erica (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Meggendorfer, Manje (Mll Munich Leukemia Laboratory) ;
Zhao, Lin-Pierre (Department of Hematology and Bone Marrow Transplantation. Hôpital Saint-Louis (França)) ;
Caballero Berrocal, Juan Carlos (Hematology Department. Hospital Universitario de Salamanca) ;
Sala, Claudia (Experimental. Diagnostic and Specialty Medicine. Dimes) ;
Maggioni, Giulia (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Bernardi, Massimo (University Vita-Salute San Raffaele (Itàlia)) ;
Di Grazia, Carmen (Irccs Ospedale Policlinico San Martino) ;
Vago, Luca (University Vita-Salute San Raffaele (Itàlia)) ;
Rivoli, Giulia (Irccs Ospedale Policlinico San Martino) ;
Borin, Lorenza (Ospedale San Gerardo) ;
D'Amico, Saverio (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Tentori, Cristina Astrid (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Ubezio, Marta (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Campagna, Alessia (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Russo, Antonio (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Mannina, Daniele (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Lanino, Luca (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Chiusolo, Patrizia (Università Cattolica Del Sacro Cuore) ;
Giaccone, Luisa (Department of Molecular Biotechnology and Health Sciences. University of Turin) ;
Voso, Maria Teresa (Tor Vergata University) ;
Riva, Maria (Asst Grande Ospedale Metropolitano Niguarda) ;
Oliva, Esther Natalie (Grande Ospedale Metropolitano Bianchi Melacrino Morelli) ;
Zampini, Matteo (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Riva, Elena (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Nibourel, Olivier (Chu Lille) ;
Bicchieri, Marinela (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Bolli, Niccolo (Department of Oncology and Hemato-Oncology. University of Milan) ;
Rambaldi, Alessandro (Azienda Ospedaliera Papa Giovanni Xxiii) ;
Passamonti, Francesco (Department of Medicine and Surgery. University of Insubria) ;
Savevski, Victor (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Santoro, Armando (Department of Biomedical Sciences. Humanitas University) ;
Germing, Ulrich (Department of Hematology. Heinrich-Heine-University. University Clinic) ;
Kordasti, Shahram (Hematology Department. DISCLIMO-Università Politecnica Delle Marche) ;
Santini, Valeria (University of Florence) ;
Diez-Campelo, María (Hospital Universitario de Salamanca) ;
Sanz, Guillermo (Hospital Universitari i Politècnic La Fe (València)) ;
Sole, F (Institut de Recerca Contra la Leucèmia Josep Carreras) ;
Kern, Wolfgang (Mll Munich Leukemia Laboratory) ;
Platzbecker, Uwe (University Hospital Leipzig) ;
Arenillas, Leonor (Department of Hematology and Bone Marrow Transplantation. Hôpital Saint-Louis) ;
Fenaux, Pierre (Department of Hematology and Bone Marrow Transplantation. Hôpital Saint-Louis) ;
Haferlach, Torsten (Mll Munich Leukemia Laboratory) ;
Castellani, Gastone (Experimental. Diagnostic and Specialty Medicine. Dimes) ;
Della Porta, Matteo Giovanni (Department of Biomedical Sciences. Humanitas University)
PURPOSEMyelodysplastic syndromes (MDS) are heterogeneous myeloid neoplasms in which a risk-adapted treatment strategy is needed. Recently, a new clinical-molecular prognostic model, the Molecular International Prognostic Scoring System (IPSS-M) was proposed to improve the prediction of clinical outcome of the currently available tool (Revised International Prognostic Scoring System [IPSS-R]). [...]
2023 -  10.1200/JCO.22.01784
Journal of Clinical Oncology, Vol. 41 Núm. 15 (20 2023) , p. 2827-2842
|
|
|
2.
|
|
10 p, 3.8 MB |
Machine Learning Improves Risk Stratification in Myelodysplastic Neoplasms : An Analysis of the Spanish Group of Myelodysplastic Syndromes
/
Mosquera Orgueira, Adrian (Complexo Hospitalario Universitario de Santiago de Compostela. Department of Hematology) ;
Perez Encinas, Manuel Mateo (Complexo Hospitalario Universitario de Santiago de Compostela. Department of Hematology) ;
Diaz Varela, Nicolas (Hospital Universitario Central de Asturias) ;
Mora, Elvira (Hospital Universitari i Politècnic La Fe (València)) ;
Díaz-Beyá, Marina (Hospital Clínic i Provincial de Barcelona) ;
Montoro, María Julia (Vall d'Hebron Institut d'Oncologia) ;
Pomares, Helena (Hematology Department. Hospital Duran i Reynals) ;
Ramos, Fernando (Department of Hematology. Hospital Universitario de León) ;
Tormo, Mar (Hospital Clínic Universitari (València)) ;
Jerez, Andres (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Nomdedeu, Josep F. (Institut d'Investigació Biomèdica Sant Pau) ;
De Miguel Sanchez, Carlos (Arabako Unibertsitate Ospitalea (Vitoria, País Basc)) ;
Leonor, Arenillas (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Cárcel, Paula (Department of Hematology. Hospital Público Universitario de la Ribera) ;
Cedena Romero, María Teresa (Hospital 12 de Octubre (Madrid)) ;
Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Rivero, Eugenia (Department of Hematology. University Hospital Arnau de Vilanova) ;
Del Orbe Barreto, Rafael Andres (Hospital Universitario Cruces Servicio de Hematología) ;
Diez-Campelo, María (Hospital Universitario de Salamanca) ;
Benlloch, Luis E. (Grupo Español de Síndromes Mielodisplásicos) ;
Crucitti, Davide (Instituto de Investigacions Sanitarias de Santiago de Compostela) ;
Valcárcel, David (Vall d'Hebron Institut d'Oncologia)
Myelodysplastic neoplasms (MDS) are a heterogeneous group of hematological stem cell disorders characterized by dysplasia, cytopenias, and increased risk of acute leukemia. As prognosis differs widely between patients, and treatment options vary from observation to allogeneic stem cell transplantation, accurate and precise disease risk prognostication is critical for decision making. [...]
2023 - 10.1097/HS9.0000000000000961
HemaSphere, Vol. 7 Núm. 10 (november 2023) , p. E961
|
|
|
3.
|
|
13 p, 1.6 MB |
Mutational Profile Enables the Identification of a High-Risk Subgroup in Myelodysplastic Syndromes with Isolated Trisomy 8
/
Toribio-Castelló, Sofía (CIBERONC. Research Group CB16/12/00233) ;
Castaño-Díez, Sandra (Hospital Clínic i Provincial de Barcelona) ;
Villaverde-Ramiro, Ángela (Universidad de Salamanca) ;
Such, Esperanza (Hospital Universitari i Politècnic La Fe (València)) ;
Arnan, Montserrat (Hospital Duran i Reynals (Hospitalet del Llobregat)) ;
Sole, F (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Díaz-Beyá, Marina (Hospital Clínic i Provincial de Barcelona) ;
Díez-Campelo, María (CIBERONC. Research Group CB16/12/00233) ;
del Rey, Mónivs (Hospital Universitario de Salamanca) ;
González, Teresa (Hospital Universitario de Salamanca) ;
Hernández-Rivas, Jesús María (CIBERONC. Research Group CB16/12/00233)
Trisomy 8 (+8) is the most frequent trisomy in myelodysplastic syndromes (MDS) and is associated with clinical heterogeneity and intermediate cytogenetic risk when found in isolation. The presence of gene mutations in this group of patients and the prognostic significance has not been extensively analyzed. [...]
2023 - 10.3390/cancers15153822
Cancers, Vol. 15 Núm. 15 (august 2023) , p. 3822
|
|
|
4.
|
|
5 p, 476.2 KB |
Incidence and prognostic impact of U2AF1 mutations and other gene alterations in myelodysplastic neoplasms with isolated 20q deletion
/
Castillo, Martín I. (Hospital Clínic Universitari (València)) ;
Ribate, Villamón E. (Hospital Clínic Universitari (València)) ;
Muñoz, Calabuig M. (Hospital Clínic Universitari (València)) ;
Santillana, Sanz G. (Hospital Universitari i Politècnic La Fe (València)) ;
Taboada, Such E. (Hospital Universitari i Politècnic La Fe (València)) ;
Casterá, Mora E. (Hospital Universitari i Politècnic La Fe (València)) ;
Abinzano, Calasanz M.J. (Universidad de Navarra) ;
Barranco, Irigoyen A. (Universidad de Navarra) ;
Nieto, Collado R. (Hospital General Universitario de Valencia) ;
Pampliega, Vara M. (Servicio de Hematología y Hemoterapia del Hospital Universitario de Cruces) ;
Blanco, M. L. (Institut d'Investigació Biomèdica Sant Pau) ;
de Andrés, Álvarez S. (NIMGenetics. Genómica y Medicina) ;
de Oteyza, Pérez J. (Hospital Universitario HM Madrid) ;
del Castillo, Bernal T. (Hospital Universidad de Asturias) ;
Font, Granada I. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Cayuela, Jerez A. (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Díez-Campelo, M. (Hospital Universitario de Salamanca) ;
Sánchez, Abellán R. (Hospital Clínic Universitari (València)) ;
Vercet, Solano C. (Hospital Clínic Universitari (València)) ;
Díaz, Tormo M. (Hospital Clínico Universitario de Valenciana) ;
Universitat Autònoma de Barcelona
Background: In myelodysplastic neoplasms (MDS), the 20q deletion [del(20q)] is a recurrent chromosomal abnormality that it has a high co-occurrence with U2AF1 mutations. Nevertheless, the prognostic impact of U2AF1 in these MDS patients is uncertain and the possible clinical and/or prognostic differences between the mutation type and the mutational burden are also unknown. [...]
2023 - 10.1002/cam4.6300
Cancer Medicine, Vol. 12 Núm. 16 (august 2023) , p. 16788-16792
|
|
|
5.
|
|
15 p, 1.0 MB |
Relevance of infections on the outcomes of patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia treated with hypomethylating agents : a cohort study from the GESMD
/
Vilorio-Marqués, Laura (Instituto de Investigación Sanitaria del Principado de Asturias) ;
Castañón Fernández, Christelle (Instituto de Investigación Sanitaria del Principado de Asturias) ;
Mora, Elvira (Hospital Universitari i Politècnic La Fe (València)) ;
Gutiérrez, Lorena (Hospital Universitario de Canarias (La Laguna)) ;
Rey Bua, Beatriz (Hospital Clínico Universitario) ;
Jiménez Lorenzo, Maria José (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Díaz-Beyá, Marina (Hospital Clínic i Provincial de Barcelona) ;
Vara Pampliega, Miriam (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Molero, Antonieta (Hospital Universitari Vall d'Hebron) ;
Sánchez-García, Joaquín (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Calabuig, Marisa (Hospital Clínic Universitari (València)) ;
Cedena, María Teresa (Hospital Universitario 12 de Octubre (Madrid)) ;
Chen-Liang, Tzu (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Díaz Santa, Johana Alejandra (Institut Catalá de Oncología) ;
Padilla, Irene (Complejo Asistencial Universitario de León) ;
Hernández, Francisca (Hospital Universitario Virgen de las Nieves (Granada)) ;
Díez, Rosana (Hospital Universitario Miguel Servet (Saragossa)) ;
Asensi, Pedro (Hospital Universitari i Politècnic La Fe (València)) ;
Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sanz, Guillermo (Hospital Universitari i Politècnic La Fe (València)) ;
Valcárcel, David (Hospital Universitari Vall d'Hebron) ;
Diez-Campelo, María (Hospital Clínico Universitario (Salamanca)) ;
Bernal, Teresa (Hospital Universitario Central de Asturias. Instituto de Investigación Sanitaria del Principado de Asturias) ;
Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras ;
Universitat Autònoma de Barcelona
Background: The consequences of infectious toxicity of hypomethylating agents (HMAs) on overall survival (OS) of patients diagnosed with high-risk myeloid neoplasms have not been thoroughly investigated. [...]
2022 - 10.1177/20406207221127547
Therapeutic Advances in Hematology, Vol. 13 (2022)
|
|
|
6.
|
|
12 p, 1.0 MB |
Guiding the global evolution of cytogenetic testing for hematologic malignancies
/
Akkari, Yassmine M.N. (Departments of Cytogenetics and Molecular Pathology. Legacy Health (Estats Units d'Amèrica)) ;
Baughn, Linda B. (Mayo Clinic) ;
Dubuc, Adrian M. (Brigham and Women's Hospital (Boston, Estats Units d'Amèrica)) ;
Smith, Adam C. (University of Toronto) ;
Mallo, Maria del Mar (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Dal Cin, Paola (Brigham and Women's Hospital (Boston, Estats Units d'Amèrica)) ;
Diez-Campelo, María (Instituto de Investigación Biomédica de Salamanca) ;
Gallego, Marta S. (Italian Hospital) ;
Granada, Isabel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Haase, Detlef (University Medical Center Göttingen) ;
Schlegelberger, Brigitte (Department of Human Genetics. Hannover Medical School) ;
Slavutsky, Irma (Institute of Experimental Medicine) ;
Mecucci, Cristina (Hematology University of Perugia) ;
Levine, Ross L. (Memorial Sloan-Kettering Cancer Center (Nova York, Estats Units d'Amèrica)) ;
Hasserjian, Robert P. (Massachusetts General Hospital (Boston)) ;
Sole, F (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Levy, Brynn (Columbia University Medical Center) ;
Xu, Xinjie (Mayo Clinic) ;
Universitat Autònoma de Barcelona
2022 - 10.1182/blood.2021014309
Blood, Vol. 139 Núm. 15 (14 2022) , p. 2273-2284
|
|
|
7.
|
|
17 p, 2.3 MB |
Analysis of Intratumoral Heterogeneity in Myelodysplastic Syndromes with Isolated del(5q) Using a Single Cell Approach
/
Acha, Pamela (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Mallo, Maria del Mar (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Manzanares Mileo, Ana (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Grau Cat, Javier (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Marcé, Silvia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Granada, Isabel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Rodríguez-Luaces, Marta (Hospital de Tortosa Verge de la Cinta) ;
Diez-Campelo, María (Hospital Universitario de Salamanca) ;
Zamora, Lurdes (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sole, F. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Palomo Sanchís, Laura (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Fuster-Tormo, Francisco (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Universitat Autònoma de Barcelona
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematological diseases. Among them, the most well characterized subtype is MDS with isolated chromosome 5q deletion (MDS del(5q)), which is the only one defined by a cytogenetic abnormality that makes these patients candidates to be treated with lenalidomide. [...]
2021 - 10.3390/cancers13040841
Cancers, Vol. 13 Núm. 4 (2021) , p. 841
|
|
|
8.
|
|
15 p, 3.4 MB |
Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS
/
Kuendgen, A. (University Hospital Duesseldorf) ;
Nomdedeu, Meritxell (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Tuechler, H. (Boltzmann Institute for Leukemia Research. Hanusch Hospital) ;
Garcia-Manero, Guillermo (MD Anderson Cancer Center) ;
Komrokji, R. S. (H Lee Moffitt Cancer Center) ;
Sekeres, M. A. (Taussig Cancer Institute. Cleveland Clinic) ;
Della Porta, M. G. (Humanitas Research Hospital (Itàlia)) ;
Cazzola, Mario (IRCCS Policlinico San Matteo Foundation) ;
DeZern, A. E. (Johns Hopkins University. Sidney Kimmel Comprehensive Cancer Center) ;
Roboz, G. J. (Weill Cornell Medicine and The New York Presbyterian Hospital) ;
Steensma, D. P. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Van de Loosdrecht, A. A. (Vrije Universiteit Amsterdam) ;
Schlenk, R. F. (Heidelberg University Hospital (Alemanya)) ;
Grau, J. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Calvo, Xavier (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Blum, S. (Lausanne University Hospital) ;
Pereira, A. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Valent, P. (Medical University of Vienna) ;
Costa, D. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Giagounidis, A. (Marienhospital Duesseldorf) ;
Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Döhner, H. (University Hospital of Ulm (Alemanya)) ;
Platzbecker, Uwe (University Hospital Leipzig) ;
Pedro, Carme (Hospital del Mar (Barcelona, Catalunya)) ;
Lübbert, M. (University Medical Center Freiburg) ;
Oiartzabal, I. (Arabako Unibertsitate Ospitalea (Vitoria, País Basc)) ;
Díez-Campelo, M. (Hospital Universitario de Salamanca) ;
Cedena, María Teresa (Hospital Universitario 12 de Octubre (Madrid)) ;
Machherndl-Spandl, S. (St Vincent's Hospital (Sydney)) ;
López-Pavía, M. (Hospital General Universitario de Valencia) ;
Baldus, C. D. (Universitätsklinikum Schleswig-Holstein (Alemanya)) ;
Martinez-de-Sola, M. (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Stauder, R. (Innsbruck Medical University) ;
Merchan, B. (Hospital Universitari Vall d'Hebron) ;
List, A. (H Lee Moffitt Cancer Center) ;
Ganster, Christina (University Medical Center Göttingen) ;
Schroeder, T. (University Hospital Duesseldorf) ;
Voso, Maria Teresa (Tor Vergata University. Department of Biomedicine and Prevention) ;
Pfeilstöcker, M. (Hanusch Krankenhaus Wien) ;
Sill, H. (Medizinische Universität Graz) ;
Hildebrandt, B. (University Duesseldorf. Institute of Human Genetics) ;
Esteve Reyner, Jordi (Hospital Clínic i Provincial de Barcelona) ;
Nomdedeu, B. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Cobo, Fernando (Hospital Quirón Teknon) ;
Haas, R. (University Hospital Duesseldorf) ;
Sole, F. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Germing, U. (University Hospital Duesseldorf) ;
Greenberg, P. L. (Stanford University Cancer Center) ;
Haase, Detlef (University Medical Center Göttingen) ;
Sanz, Guillermo (Hospital Universitari i Politècnic La Fe (València)) ;
Universitat Autònoma de Barcelona
In the current World Health Organization (WHO)-classification, therapy-related myelodysplastic syndromes (t-MDS) are categorized together with therapy-related acute myeloid leukemia (AML) and t-myelodysplastic/myeloproliferative neoplasms into one subgroup independent of morphologic or prognostic features. [...]
2020 - 10.1038/s41375-020-0917-7
Leukemia, 2020
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
